An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

  1. Rodríguez Otero, P.
  2. Towle, K.
  3. Cope, S.
  4. Caisip, C.
  5. Davies, F.E.
  6. Delforge, M.
  7. Weisel, K.
  8. Marshall, T.S.
  9. Karampampa, K.
  10. Ayers, D.
  11. Mojebi, A.
  12. Braverman, J.
  13. Farrell, J.
  14. Dhanda, D.
Revista:
Leukemia and Lymphoma

ISSN: 1029-2403,  1042-8194

Any de publicació: 2023

Volum: 64

Número: 11

Pàgines: 1864-1869

Tipus: Carta

DOI: 10.1080/10428194.2023.2235042 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus